Want to see SE:EXPRS2 full AI Analyst Report?
Top Page
ExpreS2ion Biotech Holding AB
(EXPRS2)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr1.00
▼(-94.15% Downside)
Action:Reiterated
Date:08/27/26
The score is driven primarily by weak financial performance, with persistent losses, negative gross profitability, and continued cash burn outweighing the benefit of low leverage. Technicals add pressure as the stock trades below key moving averages with a negative MACD, signaling a downtrend. Valuation provides limited support because the negative P/E reflects ongoing losses and there is no dividend yield data.
Positive Factors
Low Leverage
Very low leverage limits refinancing pressure and preserves financial flexibility. This gives ExpreS2ion more room to fund platform development or pursue partnerships without the balance-sheet constraints associated with substantial debt.
Negative Factors
Persistent Unprofitability
Negative gross profitability and large operating losses show that current revenue does not cover the cost base. Without substantial improvement in pricing, utilization or scale, the business has limited evidence of an economically sustainable model.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage limits refinancing pressure and preserves financial flexibility. This gives ExpreS2ion more room to fund platform development or pursue partnerships without the balance-sheet constraints associated with substantial debt.
Read all positive factors
ExpreS2ion Biotech Holding AB (EXPRS2) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr30.87M
Dividend YieldN/A
Average Volume (3M)19.88K
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue Growth-2.29%
EPS Growth55.71%
CountrySE
Employees19
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.83
Shares Outstanding23,748,983
10 Day Avg. Volume26,629
30 Day Avg. Volume19,883
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.27
Price to Sales (P/S)12.37
P/FCF Ratio-1.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.64
Revenue Forecast (FY)kr7.30M
ExpreS2ion Biotech Holding AB Business Overview & Revenue Model
Company Description
Based in Horsholm, Denmark, ExpreS2ion Biotech Holding AB, along with its subsidiary ExpreS2ion Biotechnologies, specializes in creating and manufacturing complex proteins for use in vaccines and diagnostic products. The company's development pipe...
How the Company Makes Money
The company makes money primarily by monetizing its protein expression platform and associated capabilities through a mix of commercial offerings and business development arrangements. Key revenue streams include: (1) Contract research/services: p...
ExpreS2ion Biotech Holding AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
63
Positive
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.84M | 3.66M | 3.01M | 7.05M | 5.09M | 12.23M |
| Gross Profit | -40.52M | -42.84M | -2.67M | 3.40M | 5.00K | 4.72M |
| EBITDA | -61.07M | -51.35M | -64.34M | -102.45M | -124.49M | -46.38M |
| Net Income | -35.91M | -38.09M | -36.04M | -91.40M | -118.61M | -43.92M |
Balance Sheet | ||||||
| Total Assets | 57.79M | 65.11M | 104.53M | 78.69M | 137.36M | 151.96M |
| Cash, Cash Equivalents and Short-Term Investments | 34.38M | 47.55M | 81.54M | 57.60M | 110.97M | 138.88M |
| Total Debt | 1.45M | 2.21M | 1.80M | 1.71M | 1.85M | 2.11M |
| Total Liabilities | 16.02M | 29.42M | 40.11M | 13.33M | 34.04M | 11.61M |
| Stockholders Equity | 41.78M | 35.69M | 64.80M | 65.36M | 103.33M | 140.35M |
Cash Flow | ||||||
| Free Cash Flow | -35.27M | -40.90M | -34.80M | -102.90M | -100.00M | -46.36M |
| Operating Cash Flow | -47.77M | -40.90M | -33.93M | -100.89M | -99.61M | -45.65M |
| Investing Cash Flow | -307.00K | 0.00 | 21.27M | -2.02M | 105.33M | -100.92M |
| Financing Cash Flow | 35.67M | 10.78M | 34.87M | 47.84M | 61.46M | 74.55M |
ExpreS2ion Biotech Holding AB Technical Analysis
Negative
17.10
Price Trends
1.42
Negative
1.73
Negative
3.27
Negative
Market Momentum
-0.04
Positive
43.07
Neutral
44.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EXPRS2, the sentiment is Negative. The current price of 17.1 is above the 20-day moving average (MA) of 1.38, above the 50-day MA of 1.42, and above the 200-day MA of 3.27, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 43.07 is Neutral, neither overbought nor oversold. The STOCH value of 44.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:EXPRS2.
ExpreS2ion Biotech Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr523.01M | 2.73 | 77.69% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr195.75M | -3.96 | -13.41% | ― | -68.66% | -137.27% | |
48 Neutral | kr446.58M | -3.93 | -17.87% | ― | ― | 15.97% | |
46 Neutral | kr356.49M | -3.95 | -30.73% | ― | -0.71% | 54.16% | |
43 Neutral | kr1.55B | -3.11 | -53.88% | ― | -87.22% | -70.29% | |
41 Neutral | kr30.87M | -0.19 | -105.07% | ― | -2.29% | 55.71% |
* Healthcare Sector Average
SE:EXPRS2
ExpreS2ion Biotech Holding AB
1.30
-6.74
-83.82%
SE:BINV
BioInvent International AB
23.50
-7.70
-24.68%
SE:XBRANE
Xbrane Biopharma AB
9.50
-25.42
-72.80%
SE:IVACC
Intervacc AB
1.05
-0.10
-9.04%
SE:IMMU
Immunicum AB
7.04
0.05
0.72%
SE:CANTA
Cantargia AB
1.86
-0.77
-29.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.